Coronary disease & ACS

Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry

Eur Heart JPublished Prospective observational registry study

Authors' conclusion

This description of the spectrum of chronic coronary syndrome patients shows that, despite high rates of prescription of evidence-based therapies, patients with both angina and prior MI are an easily identifiable high-risk group who may deserve intensive treatment.

Study context

Population
Patients with chronic coronary syndrome, CLARIFY registry (enrolled November 2009 to June 2010)
Participants
32,703 patients45 countries
Exposure
Male vs Female
Outcome
CV death or non-fatal MI
Follow-up
5 years
Methodological detailsinternational, 45 countries
  • International
  • 45 countries

Main finding

As reported in the abstract

Overall 5-year rate
8.0% (95% CI 7.7-8.3)

Observational data: associations, not effects.

Further findings

OutcomeAnginaNo anginaP value
Primary outcome by angina, patients with prior MI (subgroup)11.8% (95% CI 10.9–12.9)8.2% (95% CI 7.8–8.7)P < 0.001
Primary outcome by angina, patients without prior MI (subgroup)6.3% (95% CI 5.4–7.3)6.4% (95% CI 5.9–7.0)P > 0.99
  • Primary outcome by angina, patients with prior myocardial infarction (MI) (subgroup): interaction angina × prior MI P = 0.0016

Independent predictors of the primary outcome (Cox model)

Main independent predictors: prior hospitalization for HF, current smoking, AF, living in Central/South America, prior MI, prior stroke, DM, current angina, PAD

Prescription of evidence-based secondary prevention therapies

Prescription rates were high

Original publication

Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J. Published 3 September 2019. doi:10.1093/eurheartj/ehz660

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.